H.R. 10336, Dietary Supplement Regulatory Carve-out. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
H.R. 10336 · Mixed
What it does
This bill amends the Federal Food, Drug, and Cosmetic Act to clarify when a drug ingredient can be added to dietary supplements without triggering FDA drug-approval requirements. It creates new exceptions allowing drugs in clinical trials (Phase 2/3) to be added to supplements if the trials have been inactive for 7+ years, or if the drug was marketed as a supplement before clinical testing began. It also shifts the burden of proof to the FDA to demonstrate a violation, and makes FDA warning letters immediately challengeable in court.
The analysis names dietary supplement manufacturers — and 2 more groups — among the beneficiaries.
The trade-off
The 7-year inactive-trial exception may allow sponsors to deliberately pause clinical trials to reset the clock, converting failed or stalled drug development into supplement ingredients without FDA approval.
The analysis put a high warning level on this bill. Transparency scores 65%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Diana Harshbarger.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.